Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.47 |
| ▸ | GNRHR | P30968 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | FCER2 | P06734 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29647938 | 0.91 | GNRHR (0.50) | GPR132GNRHRMMEACECPA1 | |
| SCHEMBL30038541 | 0.87 | GNRHR (0.50) | GPR132GNRHRMMEACECPA1 | |
| SCHEMBL29390652 | 0.86 | MME (0.49) | GPR132GNRHRMMEACECPA1 | |
| SCHEMBL15344724 | 0.85 | GPR132 (0.53) | GPR132GNRHRMMEACECPA1 | |
| SCHEMBL29631784 | 0.84 | KISS1R (0.46) | GNRHRMMEACECPA1ACE2 | |
| SCHEMBL29575342 | 0.83 | MME (0.61) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL29576006 | 0.83 | MME (0.61) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL30552202 | 0.83 | KISS1R (0.47) | GNRHRMMEACECPA1ACE2 | |
| SCHEMBL15344075 | 0.83 | GPR132 (0.53) | GPR132MMEACECPA1ACE2 | |
| SCHEMBL29374168 | 0.83 | GNRHR (0.49) | GPR132GNRHRFCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | disclosed |